The National Health Surveillance Agency (Anvisa) approved this Tuesday (8) a new medication for migraine prevention. The drug atogepanto, marketed under the name Aquipta, is indicated for adults who suffer from at least four monthly migraine episodes, a condition that affects 15% of the world population.
According to the agency, atogepanto acts by blocking a pathway involved in pain transmission and in the pathophysiology of migraine, thus preventing the onset of attacks. The medication is the first in the class of CGRP antagonists in single daily dose tablet form to be approved in Brazil for migraine prophylaxis.
Development studies of the medication showed that atogepanto significantly reduces the number of monthly migraine days compared to placebo, being effective in both patients with episodic migraine and those with the chronic form of the disease. The approval represents a new therapeutic option for people who suffer from the condition in Brazil.
